World Tuberculosis Day 2024 theme “Yes! We can end TB” can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease

Apr 1, 2024 Int J Infect Dis

World Tuberculosis Day 2024 theme “Yes! We can end TB” can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease

Goletti D, Al-Abri S, Migliori GB, Arlehamn CL, Haldar P, Sundling C, da Costa C, To KW, Martineau AR, Petersen E, Zumla A, Shan Lee S

Apr 1, 2024 Int J Infect Dis

From antigens to immune responses: Shaping the future of TB detection and prevention

Panda S, Kearns K, Cheng C, Lindestam Arlehamn CS

Mar 6, 2024 bioRxiv

High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL17 against M. tuberculosis antigen

Ogongo P, Tran A, Marzan F, Gingrich D, Krone M, Aweeka F, Lindestam Arlehamn CS, Martin JN, Deeks SG, Hunt PW, Ernst JD

Mar 6, 2024 bioRxiv [Preprint]

Rare Variable M. tuberculosis Antigens induce predominant Th17 responses in human infection.

Ogongo P, Wassie L, Tran A, Columbus D, Sharling L, Ouma G, Ouma SG, Bobosha K, Lindestam Arlehamn CS, Gandhi NR, Auld SC, Rengarajan J, Day CL, Altman JD, Blumberg HM, Ernst JD; TBRU ASTRa Study Group.

Apr 18, 2024 Front Immunol

High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL-17 against M. tuberculosis antigen

Ogongo P, Tran A, Marzan F, Gingrich D, Krone M, Aweeka F, Lindestam Arlehamn CS, Martin JN, Deeks SG, Hunt PW, Ernst JD

May 13, 2024 Nat Med

High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response

Mentzer AJ, Dilthey AT, Pollard M, Gurdasani D, Karakoc E, Carstensen T, Muhwezi A, Cutland C, Diarra A, da Silva Antunes R, Paul S, Smits G, Wareing S, Kim H, Pomilla C, Chong AY, Brandt DYC, Nielsen R, Neaves S, Timpson N, Crinklaw A, Lindestam Arlehamn CS, Rautanen A, Kizito D, Parks T, Auckland K, Elliott KE, Mills T, Ewer K, Edwards N, Fatumo S, Webb E, Peacock S, Jeffery K, van der Klis FRM, Kaleebu P, Vijayanand P, Peters B, Sette A, Cereb N, Sirima S, Madhi SA, Elliott AM, McVean G, Hill AVS, Sandhu MS

Apr 19, 2024 PLoS One

Multiparameter immunoprofiling for the diagnosis and differentiation of progressive versus nonprogressive nontuberculous mycobacterial lung disease-A pilot study

Marty PK, Pathakumari B, Cox TM, Van Keulen VP, Erskine CL, Shah M, Vadiyala M, Arias-Sanchez P, Karnakoti S, Pennington KM, Theel ES, Lindestam Arlehamn CS, Peikert T, Escalante P

Jan 26, 2024 Nat Commun

Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection

Panda S, Morgan J, Cheng C, Saito M, Gilman RH, Ciobanu N, Crudu V, Catanzaro DG, Catanzaro A, Rodwell T, Perera JSB, Chathuranga T, Gunasena B, DeSilva AD, Peters B, Sette A, Lindestam Arlehamn CS

Nov 1, 2023 Curr Protoc

The megapool approach to characterize adaptive CD4+ and CD8+ T cell responses

da Silva Antunes R, Weiskopf D, Sidney J, Rubiro P, Peters B, Lindestam Arlehamn CS, Grifoni A, Sette A

Feb 13, 2024 Front Oncol

Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report

Vita S, D'Abramo A, Coppola A, Farroni C, Iori AP, Faraglia F, Sette A, Grifoni A, Lindestam Arlehamn C, Bibas M, Goletti D, Nicastri E

Feb 12, 2024 bioRxiv

PINK1 is a target of T cell responses in Parkinson’s disease

Williams GP, Michaelis T, Lima-Junior JR, Frazier A, Tran NK, Phillips EJ, Mallal SA, Litvan I, Goldman JG, Alcalay RN, Sidney J, Sulzer D, Sette A, Lindestam Arlehamn CS

Feb 6, 2024 Research News

How T cells combat tuberculosis

By tracking T cell activity, researchers uncover promising tuberculosis vaccine and drug targets